Nyxoah SA (NYXH) News

Nyxoah SA (NYXH): $10.00

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NYXH News Items

NYXH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NYXH News Highlights

  • NYXH's 30 day story count now stands at 2.
  • Over the past 7 days, the trend for NYXH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about NYXH are SA and LAW.

Latest NYXH News From Around the Web

Below are the latest news stories about Nyxoah SA that investors may wish to consider to help them evaluate NYXH as an investment opportunity.

Information on the total number of voting rights and shares

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 11, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the exercise of subscription rights and the issue of new shares. Share capital: EUR 4,431,664.69 Total number of securities carrying voting rights: 25,797,3

Yahoo | February 11, 2022

Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Mont-Saint-Guibert, Belgium – February 4, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conf

Yahoo | February 4, 2022

Nyxoah Provides General Corporate Update

Nyxoah Provides General Corporate Update Transformational 2021 positions Nyxoah for further clinical, regulatory, and commercial milestones in 2022 Mont-Saint-Guibert, Belgium – January 10, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implant

Yahoo | January 10, 2022

Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference Mont-Saint-Guibert, Belgium. – November 12, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Piper Sandler 33rd Annual V

Yahoo | November 12, 2021

Nyxoah appoints new CFO

Nyxoah appoints new CFO Mont-Saint-Guibert, Belgium – November 8, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Loïc Moreau will join Nyxoah as CFO as of January 1, 2022. Loïc will join Nyxoah from GSK, where he held leadership roles in Finance across various geographies. Prior t

Yahoo | November 8, 2021

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference Mont-Saint-Guibert, Belgium. – November 3, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Stifel 2021 Virtual Healthcare Conference o

Yahoo | November 3, 2021

Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients

INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients Notified Body DEKRA approves IFU changes to remove warning regarding CCC patients Mont-Saint-Guibert, Belgium – October 4, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea

Yahoo | October 4, 2021

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse Mont-Saint-Guibert (Belgium), September 14, 2021, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that

Yahoo | September 14, 2021

Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference

Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference Mont-Saint-Guibert (Belgium), September 13, 2021, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Cantor 2021 Global Healthcare Conf

Yahoo | September 13, 2021

Nyxoah Announces Participation in the Baird 2021 Global Healthcare Conference

PRESS RELEASE Nyxoah Announces Participation in the Baird 2021 Global Healthcare Conference Mont-Saint-Guibert, Belgium – September 2, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, and Fabian Suarez, Chief Financial Officer, will particip

Yahoo | September 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 11.9556 seconds.